Tiffany Perkins1, Jacob M Rosenberg2, Carole Le Coz3, Joseph T Alaimo4, Melissa Trofa3, Sureni V Mullegama4, Richard J Antaya5, Soma Jyonouchi3, Sarah H Elsea4, Paul J Utz6, Eric Meffre7, Neil Romberg8. 1. Department of Pediatrics, Yale University School of Medicine, New Haven, Conn. 2. Division of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, Stanford, Calif. 3. Division of Allergy Immunology, Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, Penn. 4. Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Tex. 5. Department of Pediatrics, Yale University School of Medicine, New Haven, Conn; Department of Dermatology, Yale University School of Medicine, New Haven, Conn. 6. Division of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, Stanford, Calif; Institute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Stanford, Calif. 7. Department of Immunobiology, Yale University School of Medicine, New Haven, Conn; Department of Internal Medicine, Yale University School of Medicine, New Haven, Conn. 8. Division of Allergy Immunology, Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, Penn. Electronic address: rombergn@email.chop.edu.
Abstract
BACKGROUND: Smith-Magenis syndrome (SMS) is a complex neurobehavioral disorder associated with recurrent otitis. Most SMS cases result from heterozygous interstitial chromosome 17p11.2 deletions that encompass not only the intellectual disability gene retinoic acid-induced 1 but also other genes associated with immunodeficiency, autoimmunity, and/or malignancy. OBJECTIVES: The goals of this study were to describe the immunological consequence of 17p11.2 deletions by determining the prevalence of immunological diseases in subjects with SMS and by assessing their immune systems via laboratory methods. METHODS: We assessed clinical histories of 76 subjects with SMS with heterozygous 17p11.2 deletions and performed in-depth immunological testing on 25 representative cohort members. Laboratory testing included determination of serum antibody concentrations, vaccine titers, and lymphocyte subset frequencies. Detailed reactivity profiles of SMS serum antibodies were performed using custom-made antigen microarrays. RESULTS: Of 76 subjects with SMS, 74 reported recurrent infections including otitis (88%), pneumonia (47%), sinusitis (42%), and gastroenteritis (34%). Infections were associated with worsening SMS-related neurobehavioral symptoms. The prevalence of autoimmune and atopic diseases was not increased. Malignancy was not reported. Laboratory evaluation revealed most subjects with SMS to be deficient of isotype-switched memory B cells and many to lack protective antipneumococcal antibodies. SMS antibodies were not more reactive than control antibodies to self-antigens. CONCLUSIONS: Patients with SMS with heterozygous 17p.11.2 deletions display an increased susceptibility to sinopulmonary infections, but not to autoimmune, allergic, or malignant diseases. SMS sera display an antibody reactivity profile favoring neither recognition of pathogen-associated antigens nor self-antigens. Prophylactic strategies to prevent infections may also provide neurobehavioral benefits to selected patients with SMS.
BACKGROUND:Smith-Magenis syndrome (SMS) is a complex neurobehavioral disorder associated with recurrent otitis. Most SMS cases result from heterozygous interstitial chromosome 17p11.2 deletions that encompass not only the intellectual disability gene retinoic acid-induced 1 but also other genes associated with immunodeficiency, autoimmunity, and/or malignancy. OBJECTIVES: The goals of this study were to describe the immunological consequence of 17p11.2 deletions by determining the prevalence of immunological diseases in subjects with SMS and by assessing their immune systems via laboratory methods. METHODS: We assessed clinical histories of 76 subjects with SMS with heterozygous 17p11.2 deletions and performed in-depth immunological testing on 25 representative cohort members. Laboratory testing included determination of serum antibody concentrations, vaccine titers, and lymphocyte subset frequencies. Detailed reactivity profiles of SMS serum antibodies were performed using custom-made antigen microarrays. RESULTS: Of 76 subjects with SMS, 74 reported recurrent infections including otitis (88%), pneumonia (47%), sinusitis (42%), and gastroenteritis (34%). Infections were associated with worsening SMS-related neurobehavioral symptoms. The prevalence of autoimmune and atopic diseases was not increased. Malignancy was not reported. Laboratory evaluation revealed most subjects with SMS to be deficient of isotype-switched memory B cells and many to lack protective antipneumococcal antibodies. SMS antibodies were not more reactive than control antibodies to self-antigens. CONCLUSIONS:Patients with SMS with heterozygous 17p.11.2 deletions display an increased susceptibility to sinopulmonary infections, but not to autoimmune, allergic, or malignant diseases. SMS sera display an antibody reactivity profile favoring neither recognition of pathogen-associated antigens nor self-antigens. Prophylactic strategies to prevent infections may also provide neurobehavioral benefits to selected patients with SMS.
Authors: M Di Cicco; R Padoan; G Felisati; D Dilani; E Moretti; S Guerneri; A Selicorni Journal: Int J Pediatr Otorhinolaryngol Date: 2001-06-07 Impact factor: 1.675
Authors: Javier Chinen; Monica Martinez-Gallo; Wenli Gu; Montserrat Cols; Andrea Cerutti; Lin Radigan; Li Zhang; Lorraine Potocki; Marjorie Withers; James R Lupski; Charlotte Cunningham-Rundles Journal: J Allergy Clin Immunol Date: 2011-04-22 Impact factor: 10.793
Authors: Klaus Warnatz; Axel Denz; Ruth Dräger; Moritz Braun; Christoph Groth; Guido Wolff-Vorbeck; Hermann Eibel; Michael Schlesier; Hans Hartmut Peter Journal: Blood Date: 2002-03-01 Impact factor: 22.113
Authors: Jacob M Rosenberg; Jordan V Price; Gabriela Barcenas-Morales; Lourdes Ceron-Gutierrez; Sophie Davies; Dinakantha S Kumararatne; Rainer Döffinger; Paul J Utz Journal: J Allergy Clin Immunol Date: 2015-09-11 Impact factor: 10.793
Authors: Bing He; Raul Santamaria; Weifeng Xu; Montserrat Cols; Kang Chen; Irene Puga; Meimei Shan; Huabao Xiong; James B Bussel; April Chiu; Anne Puel; Jeanine Reichenbach; László Marodi; Rainer Döffinger; Julia Vasconcelos; Andrew Issekutz; Jens Krause; Graham Davies; Xiaoxia Li; Bodo Grimbacher; Alessandro Plebani; Eric Meffre; Capucine Picard; Charlotte Cunningham-Rundles; Jean-Laurent Casanova; Andrea Cerutti Journal: Nat Immunol Date: 2010-08-01 Impact factor: 25.606